Cystic Fibrosis [2017]: Bulletin #1
This edition presents key opinion leader (KOL) views on recent developments in the cystic fibrosis market. Topics covered include: Corbus Pharmaceuticals’s announcement of positive data from a Phase II study for anabasum (Resunab), an oral synthetic, oral endocannabinoid-mimetic drug for inflammation; Vertex Pharmaceuticals’s positive data from two Phase III (EVOLVE and EXPAND) studies of the tezacaftor (VX-661)/ivacaftor and observations on development of Galapagos/AbbVie’s novel corrector, GLPG2222 and the dosing of the first patient with CF Class III (F508del and a gating mutation like G551D).
Business Questions
Business Questions
- How do KOLs view the development of anabasum (Resunab) and how will the anti-inflammatory agent fit in the CF treatment paradigm?
- What safety concerns do KOLs have with Resunab and what data is needed to convince these experts?
- How do KOLs view the potential of Vertex Pharmaceuticals’s tezacaftor/ivacaftor and what conclusions do they draw from the available data?
- What safety concerns do KOLs have for tezacaftor and how do these compare to lumacaftor?
- Where do KOLs think tezacaftor/ivacaftor will fit into the current treatment paradigm for CF patients?
- How do KOLs view Galapagos/AbbVie’s novel corrector and what challenges do they see with the development of GLPG2222?
- Will GLPG2222 combinations be practice-changing and could Galapagos/AbbVie’s challenge Vertex’s dominance in the CF space?
